Yes.
The anchor trial, published in 1993, randomized postmenopausal women with recurrent UTIs to intravaginal estriol cream or placebo and found roughly a twelvefold difference in infection rate, with the mechanism being that estrogen restores vaginal glycogen, which feeds protective lactobacilli, which lowers vaginal pH and crowds out infection-causing bacteria. A Cochrane review of over 3,000 women confirmed that vaginal estrogen reduces recurrent UTIs, while oral estrogen does not, meaning the route of delivery matters. The AUA, alongside urology and urogynecology societies, formally recommends vaginal estrogen therapy to reduce future UTI risk in perimenopausal and postmenopausal women with recurrent infections, provided there's no contraindication. This matters because recurrent UTIs drive repeated antibiotic use and antibiotic resistance, and in older women can progress to serious infection.
The clinical evidence that vaginal estrogen prevents recurrent UTIs is not seriously contested. The real gap is regulatory and behavioral: vaginal estrogen is guideline-recommended for UTI prevention but has no FDA-approved indication for that specific use, and fear generated by the old boxed warning kept many women from using a prescription they were given.
What the research shows, and which source each finding rests on
In a randomized double-blind placebo-controlled trial of 93 postmenopausal women with recurrent UTIs, intravaginal estriol cream reduced UTI episodes to 0.5 versus 5.9 per patient-year with placebo (p<0.001); lactobacilli reappeared in 61% of estriol-treated women versus 0% of placebo, and vaginal pH fell from 5.5 to 3.8.
A Cochrane review of 9 studies and 3,345 women found vaginal estrogens reduced recurrent UTIs versus placebo, while oral estrogens did not (RR 1.08).
The AUA/CUA/SUFU Recurrent UTI Guideline recommends that clinicians offer vaginal estrogen therapy to reduce future UTI risk in perimenopausal and postmenopausal women with recurrent UTIs, absent a contraindication (Moderate Recommendation, Evidence Level Grade B).
In an analysis of 1,891,956 women with recurrent UTI, the 5.1% prescribed vaginal estrogen within 2 months of a second UTI had lower odds of sepsis, hospitalization and all-cause death across every age group over 8 years of follow-up, though this is a retrospective database analysis of prescriptions, not confirmed use, and healthy-user bias is plausible.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Evidence-to-approval gap drives underuse
Narrative review literature cited in the guideline field
Vaginal estrogen is recommended by AUA, EAU and UK antimicrobial guidance for UTI prevention, yet holds no approved UTI-prevention indication with the FDA, EMA or MHRA, and this mismatch itself contributes to underuse.
What would settle it: Formal regulatory approval of a UTI-prevention indication, paired with continued patient and clinician education about the November 2025 label change, would close the remaining gap between guideline recommendation and real-world use.
What is really going on here
- I keep getting UTIs and keep getting antibiotics - why has no one offered vaginal estrogen?
- Cranberry, water and hygiene are the answer to recurrent UTIs - is that the whole answer?
Questions for your doctor
- Given my history of recurrent UTIs, am I a candidate for vaginal estrogen as prevention?
- How long does it typically take to see fewer infections after starting?
- If the first formulation doesn't suit me, can we switch rather than stop?
- What's our plan for reducing antibiotic use going forward?
Questions with no answer yet
If vaginal estrogen were granted a formal, approved indication specifically for urinary infection prevention, rather than relying on guideline recommendation alone, would that regulatory change measurably increase how often it gets prescribed for this purpose?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This exact evidence-to-approval gap is named as a documented contributor to underuse, without data testing whether formal approval, if it happened, would actually change prescribing behavior beyond what the November 2025 label change and existing guideline recommendation already produced.
What would test it: Comparing prescribing rates before and after any future formal regulatory approval of a urinary-infection-prevention indication, if one is granted.
In the very large database study finding lower odds of sepsis, hospitalization, and death associated with a vaginal estrogen prescription, how much of that association reflects actual use of the medication as prescribed, versus simply having received the prescription?
Partly studiedWhat is known: This is explicitly described as a retrospective database analysis of prescriptions, not confirmed use, with healthy-user bias plausible at effect sizes this large, without a follow-up study confirming actual medication adherence in the group.
What would test it: A study confirming actual filled prescriptions and reported use, not just the prescription being written, linked to the same serious-outcome endpoints.
Does vaginal DHEA prevent recurrent urinary infections as effectively as vaginal estrogen does, given that conference-level data have been described suggesting this but no peer-reviewed publication currently exists?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This specific claim is explicitly flagged as early-stage, conference-level data with no peer-reviewed publication located, distinct from the well-established vaginal estrogen evidence in this entry.
What would test it: A peer-reviewed randomized trial directly testing vaginal DHEA against placebo or against vaginal estrogen for urinary infection prevention specifically.
Sources
- 1.A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329(11):753-6 · Randomised trial
- 2.Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.Perrotta C, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008;(2):CD005131 · Systematic review or guideline
- 3.Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline.Anger J, Lee U, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol 2019;202(2):282-289 · Systematic review or guideline
- 4.Vaginal Estrogen Prescription is Associated with Reduced Risk of Serious Adverse Outcomes in Women of All Age Groups with Recurrent Urinary Tract Infection: An Epic Cosmos Database Analysis.LaClair J, et al. Vaginal estrogen prescription is associated with reduced risk of serious adverse outcomes in women of all age groups with recurrent UTI: an Epic Cosmos database analysis. Urology 2026 · Comparative or small study
- 5.Vaginal Estrogen for Urinary Tract Infection Prevention: A Narrative Review of Evidence, Guidelines, and Regulatory Gaps.Ghasoub R, et al. Vaginal Estrogen for Urinary Tract Infection Prevention: A Narrative Review of Evidence, Guidelines, and Regulatory Gaps. Gynecol Obstet Invest 2026:1-9 · Review, opinion or mechanism
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- What is GSM (genitourinary syndrome of menopause) and why does it affect both my vagina and my bladder?
- Is vaginal estrogen safe, and what happened to that scary warning label about stroke and cancer?
- Can I use vaginal estrogen if I've had breast cancer?
- Sex has become painful since perimenopause - is this just something I have to live with?
- What is vaginal DHEA (prasterone) and how is it different from vaginal estrogen?
- What is ospemifene, the daily pill for painful sex, and how does it work?
- Back to topic: Vaginal, sexual and urinary health